Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report

Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have demonstrated substantial effectiveness in individuals with advanced ALK-positive non-small cell lung cancer (NSCLC). However, the controversy over using ALK-TKIs for neoadjuvant therapy in ALK-positive NSCLC has not been fully exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ruiqi, Zhao, Lilan, Zhang, Juan, Guo, Lingwen, Chen, Zhizhong, Pan, Xiaojie, Chen, Wenshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685185/
https://www.ncbi.nlm.nih.gov/pubmed/38034719
http://dx.doi.org/10.1016/j.heliyon.2023.e21582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685185/
https://www.ncbi.nlm.nih.gov/pubmed/38034719
http://dx.doi.org/10.1016/j.heliyon.2023.e21582

Ejemplares similares